Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture
October 12th, 2018
8.4K views
Infection of human tissues with human immunodeficiency virus (HIV) ex vivo provides a valuable 3D model of virus pathogenesis. Here, we describe a protocol to process and infect tissue specimens from human tonsils and female genital mucosae with HIV-1 and maintain them in culture at the liquid-air interface.
Overview
This article presents a protocol for ex vivo infection of human tissues with HIV-1, specifically targeting tonsils and female genital mucosae. This method allows for the study of HIV pathogenesis while maintaining the tissue's original spatial and functional relationships.
Key Study Components
Area of Science
- Neuroscience
- Virology
- Infectious Diseases
Background
- HIV infection significantly impacts human tissues, particularly in the tonsils and genital mucosae.
- Traditional in vitro methods do not accurately reflect the complexity of HIV infection.
- Ex vivo models provide a more realistic environment for studying virus behavior.
- This approach retains the tissue's original cellular architecture for a limited time.
Purpose of Study
- To investigate the determinants of HIV transmission and pathogenesis.
- To enhance understanding of disease progression in affected tissues.
- To develop a reliable model for future HIV research.
Methods Used
- Preparation of tissue specimens from human tonsils and female genital mucosae.
- Infection of tissues with HIV-1.
- Maintenance of infected tissues in culture at the liquid-air interface.
- Utilization of gelatin sponges for tissue support during culture.
Main Results
- The ex vivo model successfully retains the spatial relationships of cells.
- Infection dynamics can be observed over a period of two to three weeks.
- This method allows for the exploration of HIV pathogenesis in a more relevant context.
- Potential for identifying new therapeutic targets and strategies.
Conclusions
- The ex vivo tissue culture model is a valuable tool for HIV research.
- It provides insights into the mechanisms of virus transmission and disease progression.
- Future studies can leverage this model to develop effective interventions.
Frequently Asked Questions
What is the significance of using ex vivo models for HIV research?
Ex vivo models retain the tissue's original architecture, providing a more accurate representation of HIV infection compared to traditional in vitro methods.
How long can the tissues be maintained in culture?
The tissues can be maintained in culture for two to three weeks, allowing for observation of infection dynamics.
What tissues are used in this study?
The study focuses on human tonsils and female genital mucosae as key sites of HIV infection.
What are the main advantages of this method?
The main advantage is the retention of spatial and functional relationships between cells, which is crucial for studying virus pathogenesis.
Can this model help in identifying new therapeutic targets?
Yes, by understanding the mechanisms of HIV transmission and pathogenesis, new therapeutic targets can be identified.
Executive Industry Relevance
Ex vivo human tissue models provide a physiologically relevant platform for studying HIV-1 pathogenesis in lymphoid and mucosal tissues, addressing limitations of in vitro systems. This approach supports target validation and mechanistic de-risking by preserving native cellular architecture and intercellular interactions critical for antiviral screening. It enables preclinical evaluation of antiviral efficacy and toxicity in a disease-relevant system, improving predictive confidence in lead identification.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by modeling HIV-1 infection in human tonsil and cervical mucosa explants.
- Operational Value: Enables functional target validation through measurement of p24 gag accumulation as a quantitative readout of viral replication.
- Predictive Value: Supports portfolio triage by identifying donor-dependent variability in infection outcomes, informing risk-adjusted advancement decisions.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for antiviral compound testing using immunoassays, qPCR, and flow cytometry.
- Operational Value: Standardizes tissue explant preparation and culture on gelatin sponges at liquid-air interface to ensure reproducibility across experiments.
- Scalability: Facilitates platform reuse for studying other pathogens like vaccinia or herpes viruses under controlled conditions.
Translational & Preclinical Research
- Translational Continuity: Models early pathogenesis in key HIV target tissues, bridging discovery to preclinical validation.
- Biomarker Alignment: Enables monitoring of HIV-1 replication via p24 gag in supernatant, supporting mechanistic de-risking of therapeutic candidates.
- Risk-Adjusted Decisions: Highlights need for donor-matched controls and technical replicates to normalize inter-donor variability in preclinical data.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical antiviral assessment, supported by its use in efficacy and toxicity studies.
- Discovery Biology: Supports hypothesis testing on virus transmission and pathogenesis determinants in lymphoid and mucosal tissues.
- Screening: Delivers assay readiness through standardized explant culture and quantitative viral readouts over two to three weeks.
- Analytics: Generates measurable outputs like p24 gag concentration, enabling statistical comparison of antiviral treatments across donors.
- Translational Research: Connects to preclinical continuity by modeling infection in physiologically relevant human tissues.
- Enterprise Reuse: Establishes a reusable platform for antimicrobial studies beyond HIV, enhancing cross-project efficiency.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by preserving spatial and functional cell relationships during infection studies.
- Operational Value: Ensures reproducibility through standardized tissue processing, explant quantification, and wash protocols.
- Strategic Value: Improves go/no-go decisions by capturing physiologic variability in antiviral response across human donors.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on efficacy in disease-relevant explant cultures.
Implementation Considerations
- Requires expertise in human tissue handling, sterile dissection, and viral inoculation under BSL-2 conditions.
- Dependent on instrumentation including incubators with CO2 control, thermoshakers, and sterile culture plates.
- Necessitates cross-team standardization of explant numbers, technical replicates, and donor-matched controls for data normalization.
- Involves adaptation considerations for tissue variability, necessitating multiple donors to account for inter-explant heterogeneity.
- Limited by progressive loss of tissue integrity over culture duration, requiring endpoint alignment with two-week culture window.
Biopharma FAQs
Why does measuring p24 gag levels matter for HIV-1 target validation?
Measuring p24 gag in culture supernatant provides a quantitative readout of HIV-1 replication, enabling assessment of antiviral efficacy in tissue explants. This metric helps distinguish productive infection from nonspecific virus absorption, supporting mechanistic de-risking of therapeutic candidates.
How does isolating the independent variable of tissue donor source improve discovery pipeline reliability?
Controlling for tissue donor source as an independent variable reduces confounding effects from inter-donor variability in HIV-1 replication. Using donor-matched controls normalizes experimental outcomes, improving data consistency when compiling results across multiple donors for statistical analysis.
What quantitative dependent variable measurements enable antiviral screening in this model?
Dependent variable measurements include p24 gag concentration via immunoassay, viral load via qPCR, and immune cell phenotyping via flow cytometry. These outputs allow comparison of antiviral treatments across conditions and time points in infected explants.
Why do replication requirements matter for cross-functional collaboration in HIV preclinical studies?
Replication using adequate explant numbers, technical replicates, and donor-matched controls ensures result reproducibility across experiments. This standardization enables reliable data sharing between discovery, toxicology, and translational teams for go/no-go decisions.
What statistical analysis capabilities are required before implementing this ex vivo model in antiviral screening?
Implementation requires capability to perform statistical analysis on data normalized using donor-matched controls to account for inter-donor variability. This includes comparing p24 gag levels across treatment groups with sufficient replicate numbers to detect significant differences in viral replication.
Chapters in this video
0:04
Title
0:49
Preparation of Gelatin Sponges
1:55
Dissection and Infection of Tonsillar Tissue with HIV-1
4:13
Dissection and Infection of Uterine Cervical Mucosa with HIV-1
7:17
Histoculture
8:33
Results: Kinetics of HIV-1 Replication in Cervical Mucosa Explants
10:02
Conclusion
